Drugs / BAT8008
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05620017 | Nov 2022 → May 2027 expected | cancer | Bio-Thera Solutions | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06341114 | Apr 2024 → Apr 2026 overdue | cancer | Bio-Thera Solutions | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAT8008 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06341114 ↗ |
| Modality | Monoclonal antibody | “Recombinant humanized anti Trop2 monoclonal antibody for injection Exetecan conjugate” NCT05620017 ↗ |
| Route | Intravenous | “Intravenous infusion” NCT05620017 ↗ |